Accessibility Menu
Arrow-Thin-Down
S&P 500
6,823.19
+0.8%
+51.64
Arrow-Thin-Down
DJI
47,388.41
+0.6%
+303.17
Arrow-Thin-Down
NASDAQ
23,583.75
+1.0%
+235.11
Arrow-Thin-Down
Bitcoin
$103,652.00
+2.4%
+$2,386.01
Arrow-Thin-Down
AAPL
$270.26
+0.1%
+$0.22
Arrow-Thin-Down
AMZN
$250.34
+0.4%
+$1.02
Arrow-Thin-Down
GOOG
$283.65
+2.0%
+$5.59
Arrow-Thin-Down
META
$640.35
+2.1%
+$13.03
Arrow-Thin-Down
MSFT
$508.84
-1.1%
-$5.49
Arrow-Thin-Down
NVDA
$200.88
+1.1%
+$2.19
Arrow-Thin-Down
TSLA
$454.59
+2.3%
+$10.33
Daily Stock GainersDaily Stock LosersMost Active Stocks

1 Powerhouse Drug in Celgene's Pipeline

By Brenton Flynn – Feb 11, 2013 at 12:13PM

Celgene discusses its potential powerhouse inflammation drug at this week's BIO CEO conference.

To kick things off at this week's BIO CEO conference, conducted by the Biotech Industry Organization, Celgene's (CELG +0.00%) CEO Bob Hugin gave a fireside chat. In this video, Motley Fool health care bureau chief Brenton Flynn highlights one of the topics discussed -- the company's new inflammation drug Apremilast -- and one of the biggest reasons why this could be a winner over the existing crop of TNF inhibitors.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services